Bracco Imaging S.p.A.
Via Egidio Folli, 50
26 articles about Bracco Imaging S.p.A.
Bracco Imaging S.p.A. received notification that the CHMP of the EMA has adopted a positive opinion recommending approval of Vueway® solution for injection for magnetic resonance imaging for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging of the CNS and several body organs.
Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Subtle Medical, Inc., a leading innovator in artificial intelligence -powered image acquisition, have entered into a global agreement in the field of magnetic resonance imaging.
Bracco Imaging announced that the American College of Radiology has classified VUEWAY® as a Group II agent within its classification of gadolinium-based contrast agents relative to the risk of development of nephrogenic systemic fibrosis.2
Preeminent Hospitals and Medical Practices Nationwide Lead in Patient Care with First Use of Bracco's VUEWAY™ (gadopiclenol) solution for injection for MRI
Bracco Imaging announced today that Wellstar Health System is among the first establishments in the nation to trial VUEWAY™ (gadopiclenol) injection, a recently FDA-approved macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).
Bracco Imaging SpA and BDP International have successfully completed a first-of-its-kind move for the Bracco Group.
Olympus announced a strategic co-marketing agreement with Monroe Township, N.J.-based Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business.
Philochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging Applications
Philochem, a subsidiary of the Philogen Group, and Bracco Imaging announce that they have entered into a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications, with proven ability to selectively detect a variety of metastatic solid tumors in cancer patients, paving the way for a new approach to tumor diagnosis.
Bracco Imaging Launches New Subsidiary, Blue Earth Therapeutics, To Advance Development Of Next Generation Therapeutic Radiopharmaceutical Technology
Innovative rhPSMA Theranostic technology has the potential to offer both diagnostic imaging and treatment for patients affected by prostate cancer.
Guerbet and Bracco Imaging announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging contrast agent.
Bracco and the Society for Advanced Body Imaging (SABI) Announce Partnership in Launch of the New SABI Bracco Mentorship Program
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, and the Society for Advanced Body Imaging announced the launch of the new SABI Bracco Mentorship Program, which aims to support the academic and professional development of SABI members throughout their careers.
Bracco Launches Global "BRACCO CARES" Initiative to Support Healthcare Professionals Through Trying Times
Bracco Imaging, a leading global company in the diagnostic imaging business, announced a new initiative called BRACCO CARES.
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, does not comment on pending litigations per its corporate policy.
Bracco Diagnostics Inc. Launches Initiative to Empower the Growth of Magnetic Resonance (MR) Practices
Customizable Media Kit for ProHance® (Gadoteridol) Injection, 279.3 mg/mL Customers to Drive Referrals and Improve Patient Satisfaction
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Bracco Imaging Expands Portfolio of Personalized Diagnostics With the Acquisition of Blue Earth Diagnostics
Bracco Imaging S.p.A. announced that it had signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK.
Blue Earth Diagnostics, a molecular imaging diagnostics company, announced that a definitive agreement has been signed for Bracco Imaging S.p.A.
Bracco Imaging S.p.A., and Shanghai Hengrui Pharmaceuticals Co. Ltd.,have signed today a collaboration agreement on new R&D activities in China.
Bracco Imaging S.p.A. announced a strategic partnership with R.A.W. S.r.l to expand its portfolio of solutions for Interventional Oncology.
Bracco Imaging Reinforces its Commitment to Innovation in Ultrasound for the Development of a New Personalized Gene Therapy
Bracco Imaging announced today that it has initiated new experimental activities in its R&D Center in Geneva, Switzerland, to explore a new application for gas-filled microbubbles in the development of personalized gene therapy for treatment of chronic dysfunctional diseases related to lipid metabolism.
Bracco Imaging acquires SurgVision expanding into the innovative field of fluorescence imaging-guided surgery
Bracco Imaging today announced the acquisition of SurgVision, a high-tech start-up focused on developing a real-time Fluorescence Image Guided Surgery platform combining targeted imaging agent and a device for efficient tumors visualization during oncology surgical procedures.